AstraZeneca’s top medical executive Cristian Massacesi will replace Bristol Myers’ current chief medical officer, Samit ...

Bristol Myers Squibb tested Cobenfy as an adjunctive treatment with atypical antipsychotics for schizophrenia in the Phase ...

Bristol-Myers Squibb Co.’s chief medical officer is stepping down from his role after six years at the company, a surprise ...

Bristol Myers Squibb has raided AstraZeneca to find its next chief medical officer, persuading Cristian Massacesi, M.D., to ...

Bristol Myers Squibb's chief medical officer, Samit Hirawat, is leaving the drugmaker to pursue new professional opportunities.

Bristol Myers Squibb is spinning off a fresh company armed with five autoimmune disease drugs and $300 million in Bain ...

Cristian Massacesi, M.D., Joins Bristol Myers Squibb as Executive Vice President, Chief Medical Officer and Head of Development ...

Detailed price information for Bristol-Myers Squibb Company (BMY-N) from The Globe and Mail including charting and trades.

Bristol Myers Squibb (NYSE:BMY) has tapped Cristian Massacesi, as executive vice president, chief medical officer, and head of development, effective August 1, 2025. Massacesi most recently served as ...

Speaking during the Fierce JPM Week virtual conference, Bristol's CMO, Samit Hirawat, said the company's deucravacitinib is a novel TYK2 inhibitor "with a very specific downstream effect of ...

PRINCETON, N.J.—Samit Hirawat, the Executive Vice President and Chief Medical (TASE: PMCN) Officer of Bristol Myers Squibb Co. (NYSE:BMY), recently made a significant purchase of the company's ...

PRINCETON, N.J.—Samit Hirawat, the Executive Vice President and Chief Medical (TASE: PMCN) Officer of Bristol Myers Squibb Co. (NYSE:BMY), recently made a significant purchase of the company's stock.